Agios Pharmaceuticals, Inc. (AGIO)

Market Cap	3.11B
Revenue (ttm)	32.87M
Net Income (ttm)	674.31M
Shares Out	57.03M
EPS (ttm)	11.80
PE Ratio	4.63
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	367,115
Open	54.29
Previous Close	54.41
Day's Range	53.82 - 55.30
52-Week Range	20.96 - 62.58
Beta	0.75
Analysts	Buy
Price Target	52.33 (-4.19%)
Earnings Date	Oct 31, 2024

About AGIO

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 24, 2013
• Employees: 386
• Stock Exchange: NASDAQ
• Ticker Symbol: AGIO
• Website: https://www.agios.com

Financial Performance

In 2023, Agios Pharmaceuticals's revenue was $26.82 million, an increase of 88.36% compared to the previous year's $14.24 million. Losses were -$352.09 million, 51.9% more than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for AGIO stock is "Buy." The 12-month stock price forecast is $52.33, which is a decrease of -4.19% from the latest price.

Price Target

$52.33

(-4.19% downside)

Analyst Consensus: Buy